Navigation Links
Creabilis Appoints Dr David Roblin as Chief Medical Officer
Date:8/4/2011

LUXEMBOURG, August 4, 2011 /PRNewswire/ --

 

Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, inflammation and pain, announces today that Dr David Roblin has been appointed Chief Medical Officer.

Dr Roblin has gained extensive experience in the pharmaceutical industry in a career spanning more than 15 years and which has seen him deliver several drugs to the market. He has held leadership roles in Pfizer and Bayer across a wide range of therapy areas in research, development and commercial roles. At Pfizer, Dr Roblin was most recently Senior Vice President, Head of Research and Site Head for European R&D. Before joining Pfizer as Head of the Company's European Clinical Research and Development organisation, Dr Roblin held the position of Head of Anti-Infectives at Bayer Medical Affairs. Dr Roblin previously practiced medicine and is a Fellow of the Royal College of Physicians and Member of the Faculty of Pharmaceutical Physicians.  

In addition to Dr Roblin's leadership roles in pharma, he has also chaired the Research Director's Group of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and was a co-founder of the Innovative Medicines Initiative, a $2bn public-private partnership with the European Commission. He is currently an advisor at NOCRI in the NHS, a non-executive director of Xceleron and an advisor to a number of venture funds.

Dr David Roblin, commenting on his appointment, said: "Creabilis has reached an exciting time in its development with its lead drug candidate, CT327, recently having demonstrated promising Phase IIa results in both psoriasis and atopic dermatitis, with ongoing studies in pain. I look forward to working with the Company as it progresses CT327 and its pipeline of potential new medicines for significant inflammatory and autoimmune conditions."

Dr Eliot Forster CEO of Creabilis said: "It is reflection of Creabilis' potential that we have been able to attract a Chief Medical Officer of David's calibre and reputation. He has vast experience not only in clinical development, but across the broader drug development pathway and pharmaceutical industry as a whole. This can only serve to benefit Creabilis as we progress our pipeline of valuable drug candidates."

About Creabilis SA

Creabilis is a clinical-stage European biotechnology company creating innovative new drugs to tackle unmet medical needs in dermatology and inflammatory diseases. Bringing together world class drug development capabilities and a rich scientific heritage, Creabilis is uniquely positioned to transform the treatment of its target diseases.

Creabilis' lead product is CT327 a novel topically applied TrkA kinase inhibitor developed using the Company's Low Systemic Exposure (LSE) technology. CT327 is currently in Phase II clinical trials in psoriasis and atopic dermatitis and is undergoing proof-of-concept studies in pain. CT340 is a potent TrkA kinase inhibitor under development for the treatment of conditions in which TrkA kinase inhibition is implicated, including inflammatory arthritis and pain. The Creabilis portfolio also includes CT637, a new approach to the treatment of significant inflammatory conditions, such as rheumatoid arthritis. Earlier-stage projects include a number of highly promising candidates for dermatological and wider indications.

Creabilis is backed by some of Europe's most highly respected life sciences investors including Sofinnova Partners and Neomed.

For more information, please visit:  http://www.creabilis-sa.com

For further information please contact:

Creabilis
Eliot Forster
eforster@creabilis-sa.com
Creabilis SA
5 rue Jean Monnet L-2810 LUXEMBOURG
                   
Citigate Dewe Rogerson
Chris Gardner or Nina Enegren
Tel: +44(0)20-7282-1050
E-mail: nina.enegren@citigatedr.co.uk


'/>"/>
SOURCE Creabilis SA
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MRIGlobal Appoints Richard A. Winegar, Ph.D., as Principal Advisor for Science
2. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
3. Imagenetix, Inc. Appoints Bill Toomey to Its Board of Directors
4. Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board
5. Crescendo Biologics Appoints Matthew Roe as Chief Business Officer
6. Synthetic Genomics Inc. Appoints Joseph Mahler as Chief Financial Officer
7. Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO
8. AquaStar Holdings, Inc. Subsidiary Appoints Former Beckman Coulter Executive as Vice President of Operations
9. Otonomy Appoints Gerald Wroblewski as Chief Operations Officer
10. Cellectis bioresearch Appoints Wako as Exclusive Distributor of its Genome Customization Solutions in Japan
11. BioNeutral Appoints Michael D. Francis, J.D. as Director to the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Feb. 12, 2016  PTC Therapeutics, Inc. ... annual STRIVE (Strategies to Realize Innovation, Vision and ... (DMD). STRIVE provides funds to patient advocacy organizations ... make meaningful contributions to the rare disease community ... of future patient advocates. Mary ...
(Date:2/11/2016)... , Feb. 11, 2016  Vermillion, Inc. (NASDAQ: ... gynecologic disease, today announced the formation of the Steering ... --> --> Pelvic masses can ... diagnosis and management. Once pregnancy is ruled out, pelvic ... and ovaries, advanced endometriosis, benign ovarian tumors and gastrointestinal ...
(Date:2/11/2016)... , Feb. 11, 2016  Wellcentive today announced ... Portland, Oregon -based community care organization ... population health analytics, quality reporting and care management ... strengthen its team of quality managers, analysts and ... the provider groups serving FamilyCare members. ...
(Date:2/11/2016)... 2016   BioInformant announces the February 2016 ... Products, Opportunities, Tools, and Technologies – Market Size, Segments, ... The first and only ... industry, BioInformant has more than a decade of historical ... by stem cell type. This powerful 175 page global ...
Breaking Biology Technology:
(Date:2/9/2016)... Feb. 9, 2016 Vigilant Solutions announces today that ... (LPR) to develop a lead in a difficult homicide case. ... data to locate the suspect vehicle. Due to the ongoing ... have been omitted at the agency,s request. ... explains, "Our victim was found deceased at an intersection here ...
(Date:2/3/2016)... --> --> Fourth quarter 2015:   ... compared with fourth quarter of 2014. Gross margin was 46% ... Earnings per share increased to SEK 6.39 (loss: 0.49). ... , --> --> January ... (233.6), up 1,142% compared with 2014. Gross margin was 43% ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 ... healthcare facilities are primarily focused on medical ... that measure point-of-care parameters. Wearable devices that ... a user,s freedom of movement are being ... sensors for human biomedical signal acquisition coupled ...
Breaking Biology News(10 mins):